What it sells
Transport technology for living cells.
Business model breakdown
Buyer: who owns the budget?
UnverifiedProcurement/lab heads at biotech, pharma, CGT manufacturers, hospitals and IVF clinics.
Trigger: what makes them buy now?
Cryopreservation damages cell viability; live-cell shipment claimed to deliver 2.5x more functional NK cells after recovery than cryopreserved transport.
Workflow: what inputs become what output?
Pack cells in a Cellbox Go (short/mid distance) or Shipper (up to 48h runtime) incubator preset to temperature and CO2, ship with data logging, receive cells under physiological conditions with no freeze-thaw.
Economics: what it saves and how it charges
Hardware sales (Cellbox Go/Shipper, new Core Edition) plus logistics services: fleet management and shipment services for live-cell logistics. No prices shown.
Distribution: how it reaches customers
Direct inquiry-led ("Get in touch"); product pages per Go Ground/Flight and Shipper Ground/Flight.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| 2026-03-06 | — | €3.5M | — | news.google.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.